Switch View
© PR Newswire
19.09.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman
News Preview
SAN FRANCISCO, Sept. 19, 2025 /PRNewswire/ -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease ("ILD"), did not meet its main goal...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC LEI: 5493003YBCY4W1IMJU04 NET ASSET VALUE The estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for Worldwide Healthcare Trust PLC at the close of business on 18 September 2025 was 353.66p (cum income). For and on behalf of the B...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
Nutex Health (NUTX) Securities Suit Alleges Fraud and Financial Misstatements-- Hagens Berman
News Preview
NUTX Investors with Losses Encouraged to Contact Hagens Berman
SAN FRANCISCO, Sept. 19, 2025 /PRNewswire/ -- Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a deceptive billing strategy to a...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
19.09.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
News Preview
100 percent of evaluable patients achieved minimal residual disease (MRD) negativity following induction therapy in updated results from the Phase 2 MajesTEC-5 study
TORONTO, Sept. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that an investigational immune-based induction regimen with TECVAYLI® (teclistamab-cqyv) and...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
19.09.2025
ISIN: IE00BTN1Y115
Medtronic PLC
MDT
LISTED
NYSE
Medtronic secures FDA approval for the Altaviva™ device, a simple experience for treating urge urinary incontinence
News Preview
The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks
GALWAY, Ireland, Sept. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today that it has received U.S. Food and Drug Administration (FD...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2025
ISIN: CA46604F1099
Izotropic Corporation
IZO
LISTED
CSE
Izotropic Closes Non-Brokered Private Placement and Engages Awareness Consultants
News Preview
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - September 19, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2025
ISIN: US29415V1098
Envoy Medical, Inc.
COCH
LISTED
NASDAQ
Envoy Medical Expands Patent Portfolio by Securing Additional European Patent for Breakthrough Cochlear Implant Technology
News Preview
Patent covers advanced signal processing for middle ear sensors, further advancing the Company's position in leveraging the ear for fully implanted hearing devicesWhite Bear Lake, Minnesota--(Newsfile Corp. - September 19, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, f...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: CNE100003N76
Shanghai Henlius Biotech, Inc.
2696
LISTED
HKSE
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
News Preview
SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEV...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2025
ISIN: US68764Y2072
OS Therapies, Inc
OSTX
LISTED
XASE
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
News Preview
New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has been invited to participate in the "Beyond the Cure: The Brave New World of Revolutionary Cancer T...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US67080N1019
Nuvation Bio Inc
NUVB
LISTED
NYSE
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZITM (taletrectinib) for the treatment of adult patients with ROS1-positive (ROS1+) unresectable, advanced and/or recurrent n...
Themefolio
Profiler
Peergroup
© Newsfile
19.09.2025
ISIN: AU0000317281
Percheron Therapeutics Limited
PER
LISTED
ASX
Edison Issues Report on Percheron Therapeutics (PER)
News Preview
London, United Kingdom--(Newsfile Corp. - September 19, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER).Percheron Therapeutics is an emerging immuno-oncology-focused biotech with a business case anchored on its recent in-licensing of HMBD-002, a Phase II-ready, potentially first-in-class anti-VISTA immune checkpoint inhibitor. HMB...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US4220091007
Healthcare Integrated Technologies, Inc.
HITC
LISTED
OTC
Signature HealthCARE Committed to Proactive Resident Safety with SafeSpace Global Corporation
News Preview
Knoxville, TN, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID:SSGC), a global leader in multimodal AI technology, is pleased to announce an expanded partnership with Signature HealthCARE. Signature HealthCARE, a family-based healthcare company known for delivering integrated care across multiple states and advancing person...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
19.09.2025
ISIN: US83548R3030
Sonnet BioTherapeutics Holdings, Inc.
SONN
LISTED
NASDAQ
Sonnet to Present at the MedInvest Biotech & Pharma Conference
News Preview
Live webcast presentation on Thursday, September 25th at 9:40 AM PT Live webcast presentation on Thursday, September 25th at 9:40 AM PT...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US91307C1027
United Therapeutics Corp
UTHR
LISTED
NASDAQ
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
News Preview
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) on Sunday, September 28, 2025, at 12:30 p.m. Eastern Time.
During t...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US4834971032
Kalvista Pharmaceuticals Inc
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the European Commission (EC) and Swiss Agency for Therapeutic Products, Swissmedic, have approved EKTERLY® (sebetralstat), a novel, oral plasma kallikrein inhibitor, for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 year...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: CA1380357048
Canopy Growth Corp
CGC
LISTED
NASDAQ
Canopy Growth Urges Shareholders to Cast their Vote for the Upcoming Annual General and Special Meeting Today
News Preview
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) today urges its shareholders to vote ahead of the upcoming annual general and special meeting of shareholders (the “Meeting”) on September 26, 2025 at 1:00 PM ET.
Canopy Needs Your Vote – Vote Today and Help Us Reach Quorum
Canopy Growth is approaching number o...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: CA24874B1085
dentalcorp Holdings Ltd.
DNTL
LISTED
TSX
Dentalcorp Declares Dividend and Announces Release Date for Third Quarter 2025 Results
News Preview
dentalcorp Holdings Ltd. (“Dentalcorp” or the “Company”) (TSX: DNTL), Canada’s largest and one of North America’s fastest growing networks of dental practices, declared a dividend and announced that it will release its third quarter 2025 financial results before the market open on November 6, 2025.
Dividend
The Company’s Board of Directors has...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: CA60255C8850
Mind Medicine (MindMed) Inc
MNMD
LISTED
NASDAQ
New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)
News Preview
Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented results from a cross-sectional retrospective study of more than 75,000 respondents from the 2022 National Health and Wellnes...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US4622221004
Ionis Pharmaceuticals Inc
IONS
LISTED
NASDAQ
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The approval follows the positive opinion of the Committee for Medicinal Products f...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the call at http://inves...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of ENFLONSIA™ (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newb...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US29089Q1058
Emergent BioSolutions Inc
EBS
LISTED
NYSE
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
News Preview
GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply agreement valued at $29 million (USD). The orders span several product offerings within Emergent’s medical countermeasures (MCM) busines...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
News Preview
Basel, 19 September - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a subcutaneous (SC) formulation of Lunsumio® (mosunetuzumab) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: KYG4818G1010
Innovent Biologics Inc
1801
LISTED
HKSE
Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes
News Preview
SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announ...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.09.2025
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
News Preview
Berlin, 19 September 2025. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, has received marketing authorization in Japan from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its GalliaPharm® 68Ge/68Ga Radionuclide Generator, t......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.09.2025
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler erhält Zulassung für GalliaPharm® in Japan
News Preview
Berlin, 19. September 2025. Die Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), ein führender Anbieter von Isotopentechnologie für die Nuklearmedizin und radiopharmazeutische Anwendungen, hat von Japans Ministerium für Gesundheit, Arbeit und Soziales (MHLW) die Marktzulassung für den GalliaPharm® 68Ge/68Ga-Radionuklidgenerator erhalte......
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US92511W1080
Verrica Pharmaceuticals Inc
VRCA
LISTED
NASDAQ
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
News Preview
– Approval triggers $10 million cash milestone payment to Verrica –...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US92243A2006
Vaxart Inc
VXRT
LISTED
NASDAQ
Vaxart Announces Withdrawal of Reverse Stock Split Proposal
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it has withdrawn its reverse stock split proposal....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: IE00BF3W0Q35
Iterum Therapeutics Plc
ITRM
LISTED
NASDAQ
Iterum Therapeutics Provides Business Update
News Preview
DUBLIN and CHICAGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a general business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US84757T1051
Spectral AI, Inc.
MDAI
LISTED
NASDAQ
Spectral AI Named to TIME’s List of World’s Top HealthTech Companies 2025
News Preview
DALLAS, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has been named to TIME’s World’s Top HealthTech Companies 2025 list. The ranking, re...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US29664W1053
Esperion Therapeutics Inc
ESPR
LISTED
NASDAQ
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
News Preview
Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US82835W1080
ARS Pharmaceuticals Inc
SBTX
LISTED
NASDAQ
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
News Preview
neffy 1 mg and 2 mg doses approved by Japanese regulators...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: CA48213Y1079
Jushi Holdings Inc.
JUSH
LISTED
CSE
Jushi Holdings Inc. Announces Grand Opening of Beyond Hello™ Parma in Ohio, Expanding its Statewide Retail Footprint
News Preview
A Media Snippet accompanying this announcement is available by clicking on this link....
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US68622V1061
Organon & Co
OGN
LISTED
NYSE
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
News Preview
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the referenc...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: FR0010259150
Ipsen SA
IPN
LISTED
EURONEXT
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
News Preview
Paris, France – 19 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval for Bylvay® (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC). PFIC is a group of rare genetic disorders in whi...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
News Preview
REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji Pharma”), has received marketing approval for three new biosimilars from...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
News Preview
REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji Pharma”), has received marketing approval for three new b...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US78397T2024
SAB Biotherapeutics, Inc.
SABS
LISTED
NASDAQ
SAB BIO Highlights Data in Multiple Presentations at EASD
News Preview
-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US83086J2006
Skye Bioscience Inc
SKYE
LISTED
NASDAQ
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
News Preview
Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerability Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerability...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US75886F1075
Regeneron Pharmaceuticals Inc
REGN
LISTED
NASDAQ
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
News Preview
Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense, also known as Zaire ebolavirus...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US87164F1057
Syndax Pharmaceuticals Inc
SNDX
LISTED
NASDAQ
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
News Preview
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia were updated to inclu...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US29358P1012
Ensign Group Inc
ENSG
LISTED
NASDAQ
The Ensign Group, Inc. Declares Quarterly Dividend of $0.0625 Per Share
News Preview
SAN JUAN CAPISTRANO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: US5845073056
Medical Care Technologies Inc.
MDCE
LISTED
OTC
Medical Care Technologies Inc. Launches AI Platform for Early Basal Cell Carcinoma Detection
News Preview
MESA, ARIZONA / ACCESS Newswire / September 19, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a pioneer in AI-powered diagnostics, today unveiled its breakthrough artificial intelligence platform for the detection and monitoring of basal cell carcinoma (BCC), the most common form of skin cancer.Though rarely fatal, untreated BCC can cause...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: SE0000872095
Swedish Orphan Biovitrum AB (publ)
SOBI
LISTED
STO
Tryngolza ® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
News Preview
STOCKHOLM, Sept. 19, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare diseases, and Ionis Pharmaceuticals, Inc. today announced that Tryngolza® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the trea...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: GB00BP2C3V08
Genflow Biosciences Plc
GENF
LISTED
LSE
Genflow Biosciences PLC Announces Holding(s) in Company
News Preview
LONDON, UK / ACCESS Newswire / September 19, 2025 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason for NotificationAn acquisition or disposal of voting rights3. Details of person subject to the notification obligationNameJonathan Mark SwannCity...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US03675P1021
Anteris Technologies Global Corp.
AVR
LISTED
NASDAQ
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
News Preview
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: FI0009014377
Orion Oyj
ORNBV
LISTED
HEL
80,802 Orion Corporation A shares converted into B shares
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 19 SEPTEMBER 2025 at 9.00 EEST ...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: CH0363463438
Idorsia Ltd
IDIA
LISTED
SIX
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
News Preview
Allschwil, Switzerland – September 19, 2025Idorsia Ltd (SIX: IDIA) announces that Swissmedic has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.1 The recommended dose is 12.5 mg orally once daily. The dos...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: GB00BP2C3V08
Genflow Biosciences Plc
GENF
LISTED
LSE
Genflow Strengthens IP Portfolio
News Preview
Genflow Strengthens Global IP Portfolio with China Patent Examination Filing for SIRT6 Variants in NASH LONDON, UK / ACCESS Newswire / September 19, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, today announces that it has filed a formal...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Comm...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US76152G1004
Reviva Pharmaceuticals Holdings, Inc.
RVPH
LISTED
NASDAQ
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
News Preview
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the prici...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US78349D1072
Rxsight Inc
RXST
LISTED
NASDAQ
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In RxSight To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in RxSight between May 7, 2024 and July 8, 2025 and would like to discuss your legal rights, call Faruqi & Fa...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
Faruqi & Faruqi Reminds Semler Scientific Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 28, 2025 - SMLR
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Semler Scientific To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Semler Scientific between March 10, 2021 and April 15, 2025 and would like to discuss your legal rig...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US90466Y1038
Unicycive Therapeutics, Inc.
UNCY
LISTED
NASDAQ
Faruqi & Faruqi Reminds Unicycive Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 - UNCY
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Unicycive To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lantheus
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lantheus To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Lantheus between February 26, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruq...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US02155H2004
Altimmune Inc
ALT
LISTED
NASDAQ
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options
If you purchased or otherwise acquired stock of Alto (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in conn...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
Faruqi & Faruqi Reminds LifeMD Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 27, 2025 - LFMD
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In LifeMD To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Fa...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Faru...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
